Replies to post #93530 on Innovation Pharmaceuticals Inc (IPIX)

[Tails]

Well, it is an absolute certainty that MDA will not replicate the lab work already done by CTIX, so a new formulation/compound(s) could very well result.

I suggest you put the question to Leo at the shareholder meeting... certainly seems possible to me.

As far as valuation assessments go, I like BK's numbers, even if they do seem low :)

Go CTIX!!

[farrell90]

CTIX's patent application includes scores of Kevetrin analogues all of which may have a number of biologic effects which could lead to new pharmaceuticals.

It would be great to have MD Anderson confirm they are studying other Kevetrin related compounds.

Good luck,Farrell

http://www.sec.gov/Archives/edgar/data/1355250/000135525009000012/exh_99-2.htm


Exhibit 99-2


Cellceutix Files Patent Application For Its Cancer Compound


BEVERLY, Mass.--(BUSINESS WIRE)--Cellceutix Corporation (OTCBB: CTIX), today announced it has filed a U.S. patent application covering pharmaceutical formulations of a compound referred to as Kevetrin™ and many novel compounds having similar structures to Kevetrin. These structures cover a large number of compounds that Cellceutix can look at as possible drug development candidates. The application covers the use of Kevetrin™ and the other compounds in various areas, including cancers. Cellceutix plans to file in other countries within a year of the U.S. filing.

George Evans, CEO stated: “This is a very exciting time for Cellceutix. The compounds covered by this patent application are structurally very different from anti-cancer agents currently on the market. Quite frankly, it took us longer than we expected to file this patent application due to the additional compounds that presented themselves as Kevetrin™ related structures. The result is a patent with new and expanded claims that will provide a strong intellectual property base for Kevetrin and a large portfolio of possible compounds for future development. In the meantime, we've been doing some very interesting experiments with Kevetrin and with our psoriasis candidate, KM-133. We anticipate announcing study results over the coming weeks."